VYNE Therapeutics (VYNE) News Today $1.67 +0.03 (+1.83%) Closing price 04:00 PM EasternExtended Trading$1.66 0.00 (-0.30%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Large Increase in Short InterestApril 2 at 2:59 AM | americanbankingnews.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | markets.businessinsider.comVYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual ConferenceMarch 20, 2025 | globenewswire.comH.C. Wainwright Sticks to Their Buy Rating for Lineage Therap (LCTX)March 12, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)March 7, 2025 | markets.businessinsider.comVYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 7, 2025 | finance.yahoo.comVYNE Therapeutics reports Q4 EPS (28c) vs (20c) last yearMarch 6, 2025 | markets.businessinsider.comVYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)March 6, 2025 | benzinga.comVYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business UpdateMarch 6, 2025 | globenewswire.comVYNE Therapeutics Inc.: VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque PsoriasisFebruary 20, 2025 | finanznachrichten.deTD Cowen Remains a Buy on VYNE Therapeutics (VYNE)February 20, 2025 | markets.businessinsider.comVyne doses first participant in Phase Ib plaque psoriasis treatment trialFebruary 20, 2025 | finance.yahoo.comVYNE Therapeutics to Participate in March Investor ConferencesFebruary 20, 2025 | globenewswire.comVYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque PsoriasisFebruary 19, 2025 | globenewswire.comAcne Vulgaris Therapeutics Market Size in the 7MM was ~USD 4,256 Million in 2023 and is projected to increase by 2034 | DelveInsightJanuary 24, 2025 | theglobeandmail.comPatrick G. Lepore Purchases 15,000 Shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) StockJanuary 17, 2025 | insidertrades.comVyne therapeutics director Patrick Lepore buys $43,800 in stockJanuary 16, 2025 | msn.comVYNE Therapeutics: Strategic Pipeline Advancements and Promising Clinical OutlookJanuary 14, 2025 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for VYNE Therapeutics (NASDAQ:VYNE)HC Wainwright restated a "buy" rating and set a $5.75 price objective on shares of VYNE Therapeutics in a research report on Tuesday.January 14, 2025 | marketbeat.comVYNE Therapeutics (VYNE) Gets a Buy from BTIGJanuary 8, 2025 | markets.businessinsider.comBuy Rating Justified for VYNE Therapeutics Due to Promising Repibresib Developments and Competitive AdvantagesJanuary 7, 2025 | markets.businessinsider.comVYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligoJanuary 7, 2025 | finance.yahoo.comHC Wainwright Reaffirms "Buy" Rating for VYNE Therapeutics (NASDAQ:VYNE)HC Wainwright reaffirmed a "buy" rating and issued a $5.75 target price on shares of VYNE Therapeutics in a research note on Monday.January 6, 2025 | marketbeat.comVYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental VitiligoJanuary 6, 2025 | globenewswire.comBTIG Initiates a Buy Rating on VYNE Therapeutics (VYNE)January 1, 2025 | markets.businessinsider.comH.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD dataDecember 25, 2024 | finance.yahoo.comVYNE Therapeutics announces results from MAD portion of Phase 1a SAD/MAD trialDecember 23, 2024 | markets.businessinsider.comVYNE Therapeutics Reports Encouraging Phase 1a Data For VYN202December 23, 2024 | markets.businessinsider.comVYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET InhibitorDecember 23, 2024 | globenewswire.comVYNE Therapeutics Inc.December 20, 2024 | thestreet.comBTIG Initiates Coverage of VYNE Therapeutics (VYNE) with Buy RecommendationNovember 19, 2024 | msn.comVYNE Therapeutics initiated with a Buy at BTIGNovember 18, 2024 | markets.businessinsider.comVYNE Therapeutics initiated with a Buy at BTIG on I&I potentialNovember 18, 2024 | markets.businessinsider.comVYNE Therapeutics Advances Clinical Pipeline in Q3 2024November 9, 2024 | markets.businessinsider.comVYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsNovember 9, 2024 | finance.yahoo.comVYNE Therapeutics: Promising Clinical Progress and Financial Stability Support Buy RatingNovember 7, 2024 | markets.businessinsider.comVYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | tmcnet.comRheumatoid Arthritis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and BarriersOctober 24, 2024 | theglobeandmail.comVera Therapeutics’ Atacicept: Promising Clinical Data and Strategic Expansion Fuel Buy RatingOctober 3, 2024 | markets.businessinsider.comBuy Rating for VYNE Therapeutics Backed by Promising Early Phase Results and Strong Clinical Development TrajectorySeptember 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for VYNE Therapeutics Amid Promising Early Data for VYN202September 12, 2024 | markets.businessinsider.comVYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET InhibitorSeptember 12, 2024 | globenewswire.comVYNE Therapeutics to Participate in September Investor ConferencesSeptember 3, 2024 | uk.finance.yahoo.comVYNE Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsAugust 16, 2024 | finance.yahoo.comBuy Rating for VYNE Therapeutics Amid Strong Financial Footing and Promising Clinical TrialsAugust 15, 2024 | markets.businessinsider.comVYNE Therapeutics Inc.: VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | finanznachrichten.deBuy Rating Affirmed for VYNE Therapeutics on Strong Financials and Promising Drug TrialsAugust 14, 2024 | markets.businessinsider.comVYNE Stock Earnings: VYNE Therapeutics Misses EPS, Beats Revenue for Q2 2024August 14, 2024 | investorplace.comVYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 14, 2024 | globenewswire.comBuy Rating for Viridian Therapeutics Backed by Physician Preference and Treatment Potential for TEDAugust 6, 2024 | markets.businessinsider.com Remove Ads Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address VYNE Media Mentions By Week VYNE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VYNE News Sentiment▼-0.140.60▲Average Medical News Sentiment VYNE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VYNE Articles This Week▼21▲VYNE Articles Average Week Remove Ads Get VYNE Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CHRS News Today VXRT News Today OPTN News Today ANIX News Today ADVM News Today FATE News Today VOR News Today BDTX News Today OCX News Today SNTI News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VYNE) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VYNE Stock Free VYNE Stock Alerts